S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections

Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT)

$2.13
+0.10 (+4.93%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.93
$2.14
50-Day Range
$1.67
$2.18
52-Week Range
$0.66
$5.78
Volume
1.70 million shs
Average Volume
935,375 shs
Market Capitalization
$1.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Summit Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
1.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.28mentions of Summit Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

919th out of 952 stocks

Pharmaceutical Preparations Industry

431st out of 445 stocks


SMMT stock logo

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.

SMMT Stock Price History

SMMT Stock News Headlines

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.95
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Summit Therapeutics: Not For Retail Investors
Q2 2023 Summit Therapeutics Inc Earnings Call
11 Stocks with Heavy Insider Buying in 2023
Q1 2023 Summit Therapeutics Inc Earnings Call
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
76
Year Founded
N/A

Profitability

Net Income
$-78,780,000.00
Pretax Margin
-271,685.00%

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
$0.14 per share

Miscellaneous

Free Float
114,237,000
Market Cap
$1.49 billion
Optionable
Optionable
Beta
-0.97
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 79)
    Co-CEO & Executive Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 53)
    M.B.A., Co-CEO, President & Director
    Comp: $934.85k
  • Mr. Ankur Dhingra (Age 47)
    Chief Financial Officer
    Comp: $668.39k
  • Mr. Manmeet Singh Soni (Age 45)
    COO & Director
  • Dr. Urte Gayko Ph.D. (Age 52)
    Chief Regulatory, Quality & Pharmacovigilance Officer?
  • Prof. Dame Kay Davies DBE (Age 72)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Shelley D. Spray (Age 58)
    Head of Corporate Education, Communications & Creative?
  • Ms. Abby Guzman Murphy
    Head of Human Resources
  • Ms. Divya Chari (Age 55)
    Head of Global Clinical Operations
  • Mr. Dave Gancarz
    Chief Business & Strategy Officer?














SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed in 2023?

Summit Therapeutics' stock was trading at $4.25 at the start of the year. Since then, SMMT shares have decreased by 49.9% and is now trading at $2.13.
View the best growth stocks for 2023 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $0.27 million during the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -